

Attachment 1 to Price Inquiry NUSI/64/PR52951/2024 -----PRODUCT LIST

No.	SUBJECT OF THE PRICE INQUIRY	QUANTITY	UNIT	QUALITY REQUIREMENTS	REQUIRED DELIVERY DATE
PART 1 - STANDARDS FOR ACTIVE SUBSTANCE NUSINERSEN					
1	5'-CCA GCA UUA UGA AAG UGA-3' unmodified RNA	100	mg	Purity - NLT 95%	not later than 31.05.2024
2	5'-CTA CTT TCA TAA TGC TGG-3' A, T, G, C: 2'-O-methoxyethyl C: 5-Methyl-C All PS	20	mg	Purity - NLT 95%	not later than 31.05.2024
3	5'-GCA CTT TCA TAA TGC TGT-3' A, T, G, C: 2'-O-methoxyethyl C: 5-Methyl-C All PS	20	mg	Purity - NLT 95%	not later than 31.05.2024
4	5'- ^{Msc} U ^{Msc} CA ^{Msc} C ^{Msc} U ^{Msc} U ^{Msc} U ^{Msc} CA ^{Msc} UAA ^{Msc} UG ^{Msc} C ^{Msc} UGG-3' A, U, G, C: 2'-O-methoxyethyl All PS	50	mg	Purity - NLT 90%	not later than 31.05.2024
5	7111.19 g/mol (free acid) 5'- ^{Msc} U ^{Msc} CA ^{Msc} C ^{Msc} U ^{Msc} U ^{Msc} U ^{Msc} CA ^{Msc} UA ^{Msc} UG ^{Msc} C ^{Msc} UGG-3' A, U, G, C: 2'-O-methoxyethyl All PS	50	mg	Purity - NLT 90%	not later than 31.05.2024
6	6723.84 g/mol (free acid) 5'- ^{Msc} U ^{Msc} CA ^{Msc} C ^{Msc} U ^{Msc} U ^{Msc} U ^{Msc} CA ^{Msc} UA ^{Msc} UG ^{Msc} C ^{Msc} UGG-3' A, U, G, C: 2'-O-methoxyethyl All PS	50	mg	Purity - NLT 90%	not later than 31.05.2024
7	7010.05 g/mol (free acid) 5'- ^{Msc} U ^{Msc} CA ^{Msc} C ^{Msc} U ^{Msc} U ^{Msc} U ^{Msc} CA ^{Msc} UAA ^{Msc} UG ^{Msc} C ^{Msc} UGG-3' A, U, G, C: 2'-O-methoxyethyl All PS	50	mg	Purity - NLT 90%	not later than 31.05.2024
8	7546.54 g/mol (free acid) 5'- ^{Msc} U ^{Msc} CA ^{Msc} C ^{Msc} U ^{Msc} U ^{Msc} U ^{Msc} CA ^{Msc} U ^{Msc} U ^{Msc} UG ^{Msc} C ^{Msc} UGG-3' A, U, G, C: 2'-O-methoxyethyl All PS	50	mg	Purity - NLT 90%	not later than 31.05.2024
9	7180.19 g/mol (free acid) 5'- ^{Msc} U ^{Msc} CA ^{Msc} C ^{Msc} U ^{Msc} U ^{Msc} U ^{Msc} CA ^{Msc} UAA ^{Msc} UG ^{Msc} C ^{Msc} UGG-3' A, U, G, C: 2'-O-methoxyethyl All PS	50	mg	Purity - NLT 90%	not later than 31.05.2024
10	7168.19 g/mol (free acid) 5'- ^{Msc} U ^{Msc} CA ^{Msc} C ^{Msc} U ^{Msc} U ^{Msc} U ^{Msc} CA ^{Msc} UAA ^{Msc} UG ^{Msc} C ^{Msc} UGG-3' A, U, G, C: 2'-O-methoxyethyl All PS	50	mg	Purity - NLT 90%	not later than 31.05.2024
11	7196.19 g/mol (free acid) 5'- ^{Msc} U ^{Msc} CA ^{Msc} C ^{Msc} U ^{Msc} U ^{Msc} U ^{Msc} CA ^{Msc} U ^{Msc} U ^{Msc} UG ^{Msc} C ^{Msc} UGG-3' A, U, G, C: 2'-O-methoxyethyl All PS	50	mg	Purity - NLT 90%	not later than 31.05.2024
12	7083.19 g/mol (free acid) 5'- ^{Msc} U ^{Msc} CA ^{Msc} C ^{Msc} U ^{Msc} U ^{Msc} U ^{Msc} CA ^{Msc} U ^{Msc} U ^{Msc} UG ^{Msc} C ^{Msc} UGG-3' A, U, G, C: 2'-O-methoxyethyl All PS	50	mg	Purity - NLT 90%	not later than 31.05.2024
13	7212.19 g/mol (free acid) 5'- ^{Msc} U ^{Msc} CA ^{Msc} C ^{Msc} U ^{Msc} U ^{Msc} U ^{Msc} CA ^{Msc} U ^{Msc} U ^{Msc} UG ^{Msc} C ^{Msc} UGG-3' A, U, G, C: 2'-O-methoxyethyl All PS	50	mg	Purity - NLT 90%	not later than 31.05.2024
14	7141.19 g/mol (free acid) 5'-DMT-TCA CTT TCA TAA TGC TGG-3' A, U, G, C: 2'-O-methoxyethyl C: 5-methyl-C All PS	50	mg	Purity - NLT 90%	not later than 31.05.2024
15	7803.12 g/mol (free acid Mw = 7429.31 g/mol) Example: 5'-UOEtMeCAMECMeU=MeU=MeC AMeUAAMEUGMeCMeUGG-3' A, U, G, C: 2'-O-methoxyethyl, OEt: 2'-O-ethyl, All PS	50	mg	Purity - NLT 90%	not later than 31.05.2024
16	Example: 5'-MeU=MeCAMECMeU=MeU=MeC AMeUAAMEUGMeCMeUGG-3' A, U, G, C: 2'-O-methoxyethyl, =: Chloral addition, All PS	50	mg	Purity - NLT 90%	not later than 31.05.2024
17	(mixture of such as N-X) 5'-[JAMeCMeU=MeU=MeC AMeUAAMEUGMeCMeUGG-3' A, U, G, C: 2'-O-methoxyethyl, All PS	500	mg	Purity - NLT 90%	not later than 31.05.2024
18	(mixture of such as N+X, cross-linked species) 5'-MeU=MeU=MeCAMECMeU=MeU=MeC AMeUAAMEUGMeCMeUGG-3' A, U, G, C: 2'-O-methoxyethyl, All PS	100	mg	Purity - NLT 90%	not later than 31.05.2024
19	Nusinersen sodium 5'-TCA CTT TCA TAA TGC TGG-3' A, T, G, C: 2'-O-methoxyethyl C: 5-Methyl-C All PS	1 000	mg	Purity - NLT 95%	not later than 31.05.2024
PART 2 - STANDARDS FOR 5-Me-DMT-2'-O-MOE-C(Bz)-CE-Phosphoramidite					
20	C ₂₈ H ₃₂ O ₉ N ₃ P CAS:166593-57-3 N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-methylcytidine	10	mg	Purity - NLT 90%	not later than 31.05.2024
21	C ₂₉ H ₃₂ O ₉ N ₃ P N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-ethyl-5-methylcytidine	10	mg	Purity - NLT 90%	not later than 31.05.2024

22	C ₃₁ H ₄₃ O ₁₀ N ₆ P N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-methoxyethyl)-5-methylcytidine	10	mg	Purity - NLT 90%	not later than 31.05.2024
23	C ₃₁ H ₄₃ O ₉ N ₆ P N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2'-O-butyl-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-5-methylcytidine	10	mg	Purity - NLT 90%	not later than 31.05.2024
24	C ₃₂ H ₄₄ O ₁₁ N ₆ P N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-[2-(2-methoxyethoxy)ethyl]-5-methylcytidine	10	mg	Purity - NLT 90%	not later than 31.05.2024
25	C ₃₈ H ₇₈ O ₁₂ N ₆ P ₂ N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-(1-cyano-4-[di(propan-2-yl)amino]-11-methyl-10-(propan-2-yl)-3,5,8-trioxa-10-aza-4,9-diphosphadodecan-9-yl)-2'-O-(2-methoxyethyl)-5-methylcytidine	10	mg	Purity - NLT 90%	not later than 31.05.2024
26	C ₃₈ H ₁₁₀ O ₂₀ N ₈ P ₂ bis[2R,3R,4R,5R][5-(4-benzamido-5-methyl-2-oxopyrimidin-1(2H)-yl)-2-[[bis(4-methoxyphenyl)(phenyl)methoxy]methyl]-4-(2-methoxyethoxy)oxolan-3-yl] ethane-1,2-diyl bis[N,N-di(propan-2-yl)(phosphoramidoite)]	10	mg	Purity - NLT 90%	not later than 31.05.2024
27	C ₃₈ H ₁₂₀ O ₂₁ N ₈ P ₂ bis[2R,3R,4R,5R][5-(4-benzamido-5-methyl-2-oxopyrimidin-1(2H)-yl)-2-[[bis(4-methoxyphenyl)(phenyl)methoxy]methyl]-4-(2-methoxyethoxy)oxolan-3-yl] oxydi(ethane-2,1-diyl) bis[N,N-di(propan-2-yl)(phosphoramidoite)]	10	mg	Purity - NLT 90%	not later than 31.05.2024
28	C ₃₈ H ₈₄ O ₁₈ N ₁₀ P ₂ (2R,3R,4R,5R)-5-(4-benzamido-5-methyl-2-oxopyrimidin-1(2H)-yl)-2-[[[(2R,3R,4R,5R)-2-(4-benzamido-5-methyl-2-oxopyrimidin-1(2H)-yl)-5-[[bis(4-methoxyphenyl)(phenyl)methoxy]methyl]-4-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]oxy]oxolan-3-yl]oxy)methyl]-4-(2-methoxyethoxy)oxolan-3-yl 2-cyanoethyl N,N-di(propan-2-yl)phosphoramidoite	10	mg	Purity - NLT 90%	not later than 31.05.2024
29	C ₃₈ H ₉₂ O ₁₇ N ₈ P (2R,3R,4R,5R)-5-(4-benzamido-5-methyl-2-oxopyrimidin-1(2H)-yl)-4-[[[(2R,3R,4R,5R)-5-(4-benzamido-5-methyl-2-oxopyrimidin-1(2H)-yl)-2-[[bis(4-methoxyphenyl)(phenyl)methoxy]methyl]-4-(2-methoxyethoxy)oxolan-3-yl]oxy]-2-[[bis(4-methoxyphenyl)(phenyl)methoxy]methyl]oxolan-3-yl 2-cyanoethyl N,N-di(propan-2-yl)phosphoramidoite	10	mg	Purity - NLT 90%	not later than 31.05.2024
30	C ₃₈ H ₉₈ O ₁₈ N ₈ P bis[2R,3R,4R,5R][5-(4-benzamido-5-methyl-2-oxopyrimidin-1(2H)-yl)-2-[[bis(4-methoxyphenyl)(phenyl)methoxy]methyl]-4-(2-methoxyethoxy)oxolan-3-yl] N,N-di(propan-2-yl)phosphoramidoite	10	mg	Purity - NLT 90%	not later than 31.05.2024
31	C ₃₀ H ₄₀ O ₁₀ N ₆ P N-benzoyl-3'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-5'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-methoxyethyl)-5-methylcytidine	10	mg	Purity - NLT 90%	not later than 31.05.2024
32	C ₃₀ H ₄₀ N ₆ O ₁₀ P CAS:163759-94-2 N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-methoxyethyl)-5-methylcytidine	40	mg	Purity ³¹ PNMR- NLT 98.0%	not later than 31.05.2024
PART 3 - STANDARDS FOR DMT-2'-O-MOE-G(iBu)-CE-Phosphoramidite					
33	C ₄₃ H ₅₈ O ₉ N ₆ P CAS:150780-67-9 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-methyl-N-(2-methylpropanoyl)guanosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
34	C ₄₈ H ₆₈ O ₉ N ₆ P 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-ethyl-N-(2-methylpropanoyl)guanosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
35	C ₄₈ H ₆₂ O ₁₀ N ₆ P 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-ethoxyethyl)-N-(2-methylpropanoyl)guanosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
36	C ₄₈ H ₆₂ O ₉ N ₆ P 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2'-O-butyl-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-N-(2-methylpropanoyl)guanosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
37	C ₄₉ H ₆₄ O ₁₁ N ₆ P 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-[2-(2-methoxyethoxy)ethyl]-N-(2-methylpropanoyl)guanosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
38	C ₄₉ H ₆₄ O ₁₁ N ₆ P 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-(1-cyano-4-[di(propan-2-yl)amino]-11-methyl-10-(propan-2-yl)-3,5,8-trioxa-10-aza-4,9-diphosphadodecan-9-yl)-2'-O-(2-methoxyethyl)-N-(2-methylpropanoyl)guanosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
39	C ₅₀ H ₁₁₀ O ₂₀ N ₁₂ P ₂ bis[2R,3R,4R,5R][2-[[bis(4-methoxyphenyl)(phenyl)methoxy]methyl]-4-(2-methoxyethoxy)-5-[2-[2-methylpropanamido]-6-oxo-1,6-dihydro-9H-purin-9-yl]oxolan-3-yl] ethane-1,2-diyl bis[N,N-di(propan-2-yl)(phosphoramidoite)] (non-preferred name)	10	mg	Purity - NLT 90%	not later than 31.05.2024
40	C ₅₁ H ₁₂₀ O ₂₁ N ₁₂ P ₂ bis[2R,3R,4R,5R][2-[[bis(4-methoxyphenyl)(phenyl)methoxy]methyl]-4-(2-methoxyethoxy)-5-[2-[2-methylpropanamido]-6-oxo-1,6-dihydro-9H-purin-9-yl]oxolan-3-yl] oxydi(ethane-2,1-diyl) bis[N,N-di(propan-2-yl)(phosphoramidoite)] (non-preferred name)	10	mg	Purity - NLT 90%	not later than 31.05.2024
41	C ₄₇ H ₆₀ O ₁₀ N ₆ P 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-3'-O-(2-methoxyethyl)-N-(2-methylpropanoyl)guanosine	10	mg	Purity - NLT 90%	not later than 31.05.2024

42	C ₆₂ H ₈₈ O ₁₈ N ₁₁ P (2R,3R,4R,5R)-2-[[bis(4-methoxyphenyl)(phenyl)methoxy)methyl]-4-(2-methoxyethoxy)-5-[2-(2-methylpropanamido)-6-oxo-1,6-dihydro-9H-purin-9-yl]oxolan-3-yl (2R,3S,5R)-2-[[bis(4-methoxyphenyl)(phenyl)methoxy)methyl]-5-[2-(2-methylpropanamido)-6-oxo-1,6-dihydro-9H-purin-9-yl]oxolan-3-yl N,N-di(propan-2-yl)phosphoramidite (non-preferred name)	10	mg	Purity - NLT 90%	not later than 31.05.2024
43	C ₆₇ H ₈₀ O ₁₈ N ₉ P 3'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-5'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-methoxyethyl)-N-(2-methylpropanoyl)guanosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
44	C ₆₇ H ₈₀ O ₁₈ N ₉ P 3'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-5'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-methoxyethyl)-2-(2-methylpropanamido)-N-(2-methylpropanoyl)adenosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
45	C ₆₇ H ₈₀ N ₉ O ₁₈ P CAS:251647-55-9 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-methoxyethyl)-N-(2-methylpropanoyl)guanosine	40	mg	Purity ³¹ PNMR- NLT 98.0%	not later than 31.05.2024
PART 4 - STANDARDS FOR DMT-2'-O-MOE-T-CE-Phosphoramidite					
46	C ₆₁ H ₈₁ O ₉ N ₄ P CAS:153631-20-0 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-5-methyl-2'-O-methyluridine	10	mg	Purity - NLT 90%	not later than 31.05.2024
47	C ₆₂ H ₈₃ O ₉ N ₄ P 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-ethyl-5-methyluridine	10	mg	Purity - NLT 90%	not later than 31.05.2024
48	C ₆₄ H ₈₇ O ₁₀ N ₄ P 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-ethoxyethyl)-5-methyluridine	10	mg	Purity - NLT 90%	not later than 31.05.2024
49	C ₆₄ H ₈₇ O ₉ N ₄ P 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2'-O-butyl-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-5-methyluridine	10	mg	Purity - NLT 90%	not later than 31.05.2024
50	C ₆₅ H ₈₉ O ₁₁ N ₄ P 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-[2-(2-methoxyethoxy)ethyl]-5-methyluridine	10	mg	Purity - NLT 90%	not later than 31.05.2024
51	C ₆₁ H ₇₃ O ₁₂ N ₆ P ₂ 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-(1-cyano-4-[di(propan-2-yl)amino]-11-methyl-10-(propan-2-yl)-3,5,8-trioxa-10-aza-4,9-diphosphadodecan-9-yl]-2'-O-(2-methoxyethyl)-5-methyluridine	10	mg	Purity - NLT 90%	not later than 31.05.2024
52	C ₆₂ H ₁₀₆ O ₂₀ N ₉ P ₂ bis(2R,3R,4R,5R)-2-[[bis(4-methoxyphenyl)(phenyl)methoxy)methyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)oxolan-3-yl] ethane-1,2-diyl bis[N,N-di(propan-2-yl)(phosphoramidite)]	10	mg	Purity - NLT 90%	not later than 31.05.2024

53	C ₆₄ H ₁₁₀ O ₁₁ N ₆ P ₂ bis[2R,3R,4R,5R]-2-[[bis(4-methoxyphenyl)(phenyl)methoxy)methyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)oxolan-3-yl] oxydi(ethane-2,1-diyl) bis[N,N-di(propan-2-yl)](phosphoramidoite)]	10	mg	Purity - NLT 90%	not later than 31.05.2024
54	C ₆₂ H ₈₈ O ₁₈ N ₆ P ₂ {2R,3R,4R,5R}-2-[[bis(4-methoxyphenyl)(phenyl)methoxy)methyl]-4-[[{2R,3R,4R,5R}-3-[[{[(2-cyanoethoxy)]di(propan-2-yl)amino]phosphanyl]oxy}-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)oxolan-2-yl]methoxy]-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)oxolan-3-yl 2-cyanoethyl N,N-di(propan-2-yl)]phosphoramidoite	10	mg	Purity - NLT 90%	not later than 31.05.2024
55	C ₆₂ H ₈₈ O ₁₇ N ₆ P {2R,3R,4R,5R}-2-[[bis(4-methoxyphenyl)(phenyl)methoxy)methyl]-4-[[{2R,3R,4R,5R}-3-[[{[(2-cyanoethoxy)]di(propan-2-yl)amino]phosphanyl]oxy}-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)oxolan-2-yl]methoxy]-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)oxolan-3-yl 2-cyanoethyl N,N-di(propan-2-yl)]phosphoramidoite	10	mg	Purity - NLT 90%	not later than 31.05.2024
56	C ₆₄ H ₈₈ O ₁₈ N ₆ P bis[2R,3R,4R,5R]-2-[[bis(4-methoxyphenyl)(phenyl)methoxy)methyl]-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)oxolan-3-yl] N,N-di(propan-2-yl)]phosphoramidoite	10	mg	Purity - NLT 90%	not later than 31.05.2024
57	C ₆₃ H ₈₅ O ₁₀ N ₆ P 3',5'-bis-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2'-O-(2-methoxyethyl)-5-methyluridine	10	mg	Purity - NLT 90%	not later than 31.05.2024
58	C ₆₅ H ₈₆ O ₁₁ N ₂ 3'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-5'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-methoxyethyl)-5-methyluridine	10	mg	Purity - NLT 90%	not later than 31.05.2024
59	C ₆₃ H ₈₅ O ₁₀ N ₆ P CAS:163878-63-5 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-methoxyethyl)-5-methyluridine	40	mg	Purity ³¹ PNMR- NLT 98.0%	not later than 31.05.2024
PART 5 - STANDARDS FOR DMT-2'-O-MOE-A(Bz)-CE-Phosphoramidite					
60	C ₆₈ H ₁₀₄ O ₉ N ₃ P CAS:110782-31-5 N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-methyladenosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
61	C ₆₉ H ₈₆ O ₉ N ₃ P N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-ethyladenosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
62	C ₆₁ H ₆₀ O ₉ N ₃ P N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-ethoxyethyl)adenosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
63	C ₆₁ H ₆₀ O ₉ N ₃ P N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2'-O-butyl-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]adenosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
64	C ₆₂ H ₆₂ O ₁₀ N ₃ P N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-[2-(2-methoxyethoxy)ethyl]adenosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
65	C ₆₈ H ₇₀ O ₁₁ N ₆ P ₂ N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[1-cyano-4-[di(propan-2-yl)amino]-11-methyl-10-(propan-2-yl)-3,5,8-trioxo-10-aza-4,9-diphosphadodecan-9-yl]-2'-O-(2-methoxyethyl)adenosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
66	C ₆₆ H ₁₁₁ O ₁₃ N ₁₂ P ₂ bis[2R,3R,4R,5R][5-(6-benzamido-9H-purin-9-yl)-2-[[bis(4-methoxyphenyl)(phenyl)methoxy)methyl]-4-(2-methoxyethoxy)oxolan-3-yl] ethane-1,2-diyl bis[N,N-di(propan-2-yl)](phosphoramidoite)]	10	mg	Purity - NLT 90%	not later than 31.05.2024
67	C ₆₈ H ₁₁₀ O ₁₃ N ₁₂ P ₂ bis[2R,3R,4R,5R][5-(6-benzamido-9H-purin-9-yl)-2-[[bis(4-methoxyphenyl)(phenyl)methoxy)methyl]-4-(2-methoxyethoxy)oxolan-3-yl] oxydi(ethane-2,1-diyl) bis[N,N-di(propan-2-yl)](phosphoramidoite)]	10	mg	Purity - NLT 90%	not later than 31.05.2024
68	C ₆₀ H ₅₈ O ₉ N ₃ P CAS:256224-01-8 N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-3'-O-(2-methoxyethyl)adenosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
69	C ₆₄ H ₇₂ O ₁₀ N ₃ P N-[bis(4-methoxyphenyl)(phenyl)methyl]-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-methoxyethyl)adenosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
70	C ₆₈ H ₁₀₄ O ₉ N ₃ P 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-methoxyethyl)adenosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
71	C ₆₈ H ₈₆ O ₁₆ N ₁₁ P bis[2R,3R,4R,5R][5-(6-benzamido-9H-purin-9-yl)-2-[[bis(4-methoxyphenyl)(phenyl)methoxy)methyl]-4-(2-methoxyethoxy)oxolan-3-yl] N,N-di(propan-2-yl)]phosphoramidoite	10	mg	Purity - NLT 90%	not later than 31.05.2024
72	C ₆₀ H ₅₈ O ₉ N ₃ P N-benzoyl-3'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-5'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-methoxyethyl)adenosine	10	mg	Purity - NLT 90%	not later than 31.05.2024
73	C ₆₀ H ₅₈ N ₃ O ₉ P CAS:251647-53-7 N-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2-cyanoethoxy)[di(propan-2-yl)amino]phosphanyl]-2'-O-(2-methoxyethyl)adenosine	40	mg	Purity ³¹ PNMR- NLT 98.0%	not later than 31.05.2024